BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee NY, Suk KT. The Role of the Gut Microbiome in Liver Cirrhosis Treatment. Int J Mol Sci 2020;22:E199. [PMID: 33379148 DOI: 10.3390/ijms22010199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lu H, Chen L, Pan X, Yao Y, Zhang H, Zhu X, Lou X, Zhu C, Wang J, Li L, Wu Z. Lactitol Supplementation Modulates Intestinal Microbiome in Liver Cirrhotic Patients. Front Med (Lausanne) 2021;8:762930. [PMID: 34722597 DOI: 10.3389/fmed.2021.762930] [Reference Citation Analysis]
2 Chen S, He Z, Xie W, Chen X, Lin Z, Ma J, Liu Z, Yang S, Wang Y. Ginsenoside Rh2 attenuates CDAHFD-induced liver fibrosis in mice by improving intestinal microbial composition and regulating LPS-mediated autophagy. Phytomedicine 2022;101:154121. [PMID: 35489327 DOI: 10.1016/j.phymed.2022.154121] [Reference Citation Analysis]
3 Kreisel W, Lazaro A, Trebicka J, Grosse Perdekamp M, Schmitt-Graeff A, Deibert P. Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. Int J Mol Sci 2021;22:10372. [PMID: 34638713 DOI: 10.3390/ijms221910372] [Reference Citation Analysis]
4 Chen T, Li R, Chen P. Gut Microbiota and Chemical-Induced Acute Liver Injury. Front Physiol 2021;12:688780. [PMID: 34122150 DOI: 10.3389/fphys.2021.688780] [Reference Citation Analysis]
5 Gupta H, Min B, Ganesan R, Gebru YA, Sharma SP, Park E, Won S, Jeong J, Lee S, Cha M, Kwon G, Jeong M, Hyun J, Eom J, Park H, Yoon S, Choi M, Kim D, Suk K. Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role. Biomedicines 2022;10:550. [DOI: 10.3390/biomedicines10030550] [Reference Citation Analysis]
6 Zhang Y, Sun F, Li X, Liu Q, Chen Z, Guo Y. Identification of Molecular Subgroups in Liver Cirrhosis by Gene Expression Profiles. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon.118535] [Reference Citation Analysis]
7 Philips CA, Augustine P. Gut Barrier and Microbiota in Cirrhosis. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.08.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang B, Dong W, Ma L, Dong Y, Wang S, Yuan Y, Ma Q, Xu J, Yan W, Nan J, Zhang Q, Xu W, Ma B, Chu Y, Zhang J, Li L, Li Y. Prevalence and Genetic Diversity of Clostridium perfringens Isolates in Hospitalized Diarrheal Patients from Central China. Infect Drug Resist 2021;14:4783-93. [PMID: 34815676 DOI: 10.2147/IDR.S338593] [Reference Citation Analysis]
9 Asai N, Suematsu H, Sakanashi D, Kato H, Shiota A, Hagihara M, Koizumi Y, Yamagishi Y, Mikamo H. Empyema and bacteremia caused by Aeromonas hydrophila: Case report and review of the literature. J Infect Chemother 2022:S1341-321X(21)00365-2. [PMID: 35031202 DOI: 10.1016/j.jiac.2021.12.029] [Reference Citation Analysis]
10 Manzoor R, Ahmed W, Afify N, Memon M, Yasin M, Memon H, Rustom M, Al Akeel M, Alhajri N. Trust Your Gut: The Association of Gut Microbiota and Liver Disease. Microorganisms 2022;10:1045. [DOI: 10.3390/microorganisms10051045] [Reference Citation Analysis]
11 Shu W, Shanjian C, Jinpiao L, Qishui O. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100676] [Reference Citation Analysis]
12 Trifylli E, Koustas E, Papadopoulos N, Sarantis P, Aloizos G, Damaskos C, Garmpis N, Garmpi A, Karamouzis MV. An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma. Life 2022;12:665. [DOI: 10.3390/life12050665] [Reference Citation Analysis]